Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Phathom Pharmaceuticals Inc PHAT

Healthcare
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are... see more

Recent & Breaking News (NDAQ:PHAT)

Phathom Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire May 28, 2020

Phathom Pharmaceuticals Reports First Quarter 2020 Results

GlobeNewswire May 12, 2020

Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference

GlobeNewswire April 9, 2020

Phathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business Updates

GlobeNewswire March 19, 2020

Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020

GlobeNewswire February 25, 2020

Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund

PR Newswire January 16, 2020

Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer

Business Wire January 6, 2020

Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection

Business Wire December 23, 2019

Phathom Pharmaceuticals Expands Leadership Team and Announces Board Transition

Business Wire December 2, 2019

Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Erosive Esophagitis

Business Wire December 2, 2019

Phathom Pharmaceuticals to Present at Evercore ISI 2019 HealthCONx Conference

Business Wire November 26, 2019

Phathom Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Business Wire November 25, 2019

Phathom Pharmaceuticals to Present at Jefferies 2019 London Healthcare Conference

Business Wire November 13, 2019

Phathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire October 29, 2019

Phathom Pharmaceuticals Announces Pricing of Initial Public Offering

Business Wire October 24, 2019